Bolt Biotherapeutics, Inc. (BOLT)
|Net Income (ttm)||-39.06M|
|Trading Day||March 5|
|Day's Range||26.55 - 30.40|
|52-Week Range||22.63 - 35.88|
Bolt Biotherapeutics Announces Closing of Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
REDWOOD CITY, Calif., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage immuno-oncology company, announced today the closing of its initial public o...
REDWOOD CITY, Calif.-- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage immuno-oncology company, announced...
Bolt Biotherapeutics, a Phase 1/2 biotech developing targeted therapies for solid tumors, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
Bolt Biotherapeutics, Inc. has filed to go public with an IPO on the NASDAQ.
We are a clinical-stage immuno-oncology company developing tumor-targeted therapies. Our proprietary Boltbody Immune-Stimulating Antibody Conjugate, or ISAC, approach is pioneering a new category of immunotherapies that combines the precision of antibody targeting with the strength of the innate and adaptive immune systems by activating and recruiting myeloid cells, thereby re-programming the tumor microenvironment to invoke an adaptive immune response. We believe that this process leads to the development of systemic immunological memory achi... [Read more...]
|IPO Date |
Feb 5, 2021
Randall C. Schatzman, Ph.D.
|Stock Exchange |
|Ticker Symbol |